Published in:
01-02-2004 | Poster presentation
Early treatment with Drotrecogin alfa (activated) was associated with reduced hospital resource use in adult severe sepsis patients with two or more organ dysfunctions at baseline: results from ENHANCE
Authors:
J Vincent, J Dhainaut, C Putensen, A Artigas, R Fumagalli, M Turlo, K Wong, J Janes
Published in:
Critical Care
|
Special Issue 1/2004
Login to get access
Excerpt
In a phase 3 trial (PROWESS, n = 1690), Drotrecogin alfa (activated) (DrotAA) was associated with a significant survival improvement and favorable benefit–risk profile compared with placebo in adult patients with severe sepsis receiving standard supportive care. A global, single-arm, open-label trial of DrotAA in adult patients with severe sepsis (ENHANCE, n = 2378) was subsequently conducted at 361 sites in 25 countries, and hospital resource usage was assessed with respect to the timing of DrotAA administration. …